BSE Live
Mar 12, 16:01Prev. Close
195.30
Open Price
192.70
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 12, 15:52Prev. Close
195.32
Open Price
194.74
Bid Price (Qty.)
196.06 (148)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Viyash Scientific (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 30.37 | 5.53 | 2.74 | 9.07 | 5.42 | |
| Net CashFlow From Operating Activities | 29.74 | 10.64 | 0.05 | 2.40 | 7.16 | |
| Net Cash Used In Investing Activities | -29.80 | -29.05 | -36.10 | -8.08 | -2.50 | |
| Net Cash Used From Financing Activities | 7.10 | 18.38 | 34.21 | 9.47 | -5.45 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 7.04 | -0.04 | -1.84 | 3.80 | -0.80 | |
| Cash And Cash Equivalents Begin of Year | 5.42 | 4.01 | 5.85 | 2.05 | 2.85 | |
| Cash And Cash Equivalents End Of Year | 12.47 | 3.98 | 4.01 | 5.85 | 2.05 |
18.02.2026
Viyash Scientif Consolidated December 2025 Net Sales at Rs 858.41 crore, up 119.65% Y-o-Y
16.02.2026
Viyash Scientif Standalone December 2025 Net Sales at Rs 341.64 crore, up 841.94% Y-o-Y
02.12.2025
Sequent Scienti Standalone September 2025 Net Sales at Rs 34.03 crore, down 18.96% Y-o-Y
22.08.2025
Sequent Scienti Standalone June 2025 Net Sales at Rs 41.07 crore, down 28.78% Y-o-Y
18.02.2026
Viyash Scientif Consolidated December 2025 Net Sales at Rs 858.41 crore, up 119.65% Y-o-Y
16.02.2026
Viyash Scientif Standalone December 2025 Net Sales at Rs 341.64 crore, up 841.94% Y-o-Y
02.12.2025
Sequent Scienti Standalone September 2025 Net Sales at Rs 34.03 crore, down 18.96% Y-o-Y
22.08.2025
Sequent Scienti Standalone June 2025 Net Sales at Rs 41.07 crore, down 28.78% Y-o-Y
11.03.2026
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
11.03.2026
10.03.2026
Beyond the price war, Indian drug companies gearing up to win the GLP-1 retention game
10.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities